Topical management in the postoperative care after endoscopic rhinosurgery

Aleksandrov, A. N.; Karpishchenko, S. А.; Vereshchagina, O.E.; Bolozneva, E.V.; Shchelkunova, M.A.

doi:10.33848/foliorl23103825-2021-27-3-57-52

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is no doubt that FESS procedures in the GA setting require local tissue bleeding control 4–7,16 . There are a few ways to reduce BI: hemostatic therapy, 17,18 induced hypotension, 3,7,9 administration of beta blockers, 19–21 or glucocorticoids 22,23 .…”

Section: Discussionmentioning

confidence: 99%

“…All FESS procedures were performed by the same surgeon, who did not know about terlipressin administration and evaluated the BI on a 6‐point scale of mean values (Fromme‐Boezaart Score) 5 . In this scale, 0 points indicate no bleeding in the surgical field, whereas 5 points indicate severe bleeding that completely reduces visibility and makes it impossible to continue the procedure.…”

Section: Methodsmentioning

confidence: 99%

“…The key issues with FESS concern cases of local bleeding. Even small amounts of bleeding can considerably limit surgical field visualization, thus disrupting the surgical plan and causing complications 4,5 . Increased extent of bleeding may correlate with more intensive peripheral blood flow caused by nitroglycerin or a greater depth of anesthesia, particularly the inhalational type 6,7 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Intraoperative Bleeding Control with Terlipressin in Functional Endoscopic Sinus Surgery

et al. 2023

View full text Add to dashboard Cite

ObjectiveTo evaluate the use of terlipressin for intraoperative bleeding reduction in functional endoscopic sinus surgery (FESS).MethodsThis prospective, randomized, single‐center, single‐blinded cohort study included 74 cases of FESS performed under general anesthesia (GA). The patients were randomized into two groups: WT (without terlipressin, n = 39) and T (with 200 μg terlipressin, n = 35). Bleeding intensity (BI) was assessed using a 6‐point scale. Heart rate (HR), mean blood pressure (MBP), perfusion index (PI), and BI were recorded at 10, 30, and 60 min after surgery. A BI score ≥2 qualified as significant.ResultsThe T group had significantly higher MBP compared with the WT group, but HR values did not differ significantly. PI and BI scores were significantly reduced in the T group compared with the WT group. The risk of significant bleeding in the treatment group was 35.5 times lower (odds ratio [OR], 0.028; 95% confidence interval [CI], 0.006–0.138) at 30 min and 7.1 times lower (OR, 0.140; 95% CI, 0.049–0.402) at 60 min. The prognostic model for significant bleeding at 60 min showed that only terlipressin played a significant role in bleeding control (p < 0.05). The model predicted a 13.9‐fold decrease in significant bleeding risk in the T group.ConclusionLow doses (200 μg) of terlipressin reduced intraoperative bleeding without decreasing blood pressure during FESS under GA.Level of Evidence2 Laryngoscope, 2023

show abstract